Jan 22 2007
Heska Corporation has announced that it has completed the sale of its rights in a worldwide patent portfolio covering a number of major allergens and the genes that encode them to Allergopharma Joachim Ganzer KG for an undisclosed sum.
As part of the agreement, Heska Corporation has exclusively licensed veterinary rights to the portfolio.
"This agreement provides us with additional capital as well as exclusive veterinary rights to the technology underlying this patent portfolio," said Robert Grieve, Heska's Chairman and CEO. "We intend to continue to focus our resources on the companion animal health market."
"We are committed to being a leader in the allergy market," commented Joachim Ganzer, Managing Partner of Allergopharma. "We believe this patent portfolio will provide legal protection for our strong pipeline of products that will improve diagnosis and treatment of allergic diseases in humans."
http://www.heska.com and http://www.allergopharma.com